June 2018 in “Surgical Case Reports” S-1 treatment led to a complete response in pancreatic cancer with manageable side effects.
November 2023 in “Indian Dermatology Online Journal” This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.
June 2025 in “Journal of Cosmetic Dermatology” This study found that among various treatments for male androgenetic alopecia, dutasteride 0.5 mg/day was the most effective option overall. Additionally, among FDA-approved treatments, topical minoxidil 5% was the most effective topical therapy, and finasteride 1 mg/day was the most effective oral therapy.
January 2026 in “International Society of Hair Restoration Surgery” This article discusses the controversy surrounding mesotherapy for hair growth, highlighting the lack of rigorous clinical trials, and reports no new research findings.
March 2025 in “Canadian dermatology today.” In this case series, treatment with clascoterone cream 1% was reported to be effective and well tolerated for diverse acne vulgaris patients, improving clinical outcomes whether used alone or in combination with other therapies, and addressing various other skin conditions.